Small-molecule anti-inflammatory drug compositions for the treatment of asthma: a patent review (2013 – 2014)

Bibliography

• WHO. Asthma. World Health Organ Fact Sheet 307. 2013. Available from: http://www.who.int/mediacentre/factsheets/fs307/en/
   Google Scholar
• WHO. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. 2007. Available from: http://books.google.com/books?hl=en&lr=&id=gdj5iU5FrXEC&pgis=1
   Google Scholar
• Grammer LC, Greenberger PA. Patterson’s allergic diseases. 7th edition. Lippincott, Williams & Wilkins, UK; 2009
   Google Scholar
• Montuschi P. Leukotrienes, antileukotrienes and asthma. Mini Rev Med Chem 2008;8:647-56
   PubMed Web of Science ®Google Scholar
• Walsh GM. An update on biologic-based therapy in asthma. Immunotherapy 2013;5:1255-64
   PubMed Web of Science ®Google Scholar
• PR Newswire. Asthma Treatment Market (Drug) Worth $23 Billion by 2023. Available from: http://www.prnewswire.com/news-releases/asthma-treatment-market-drug-worth-23-billion-by-2023-284128681.html
   Google Scholar
• Barnes PJ. Severe asthma: advances in current management and future therapy. J Allergy Clin Immunol 2012;129:48-59
   PubMed Web of Science ®Google Scholar
• Montuschi P. Toward a personalized pharmacotherapy of respiratory diseases. Front Pharmacol 2010;1:131
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Rogliani P, Matera MG. β2-agonist therapy in lung disease. Am J Respir Crit Care Med 2013;187:690-6
   PubMed Web of Science ®Google Scholar
• Prat M, Gavaldà A, Fonquerna S, Miralpeix M. Inhaled muscarinic antagonists for respiratory diseases: a review of patents and current developments (2006-2010). Expert Opin Ther Pat 2011;21:1543-73
   PubMed Web of Science ®Google Scholar
• Norman P. Boehringer Ingleheim’s selective glucocorticoid receptor agonist development candidate: evaluation of WO2010141331, WO2010141332 and WO2010141333. Expert Opin Ther Pat 2011;21:1137-42
   PubMed Web of Science ®Google Scholar
• Norman P. Spleen tyrosine kinase inhibitors: a review of the patent literature 2010-2013. Expert Opin Ther Pat 2014;24:573-95
   PubMed Web of Science ®Google Scholar
• Bühler S, Laufer SA. p38 MAPK inhibitors: a patent review (2012-2013). Expert Opin Ther Pat 2014;24:535-54
   PubMed Web of Science ®Google Scholar
• Singh R, Masuda ES, Payan DG. Discovery and development of spleen tyrosine kinase (SYK) inhibitors. J Med Chem 2012;55:3614-43
   PubMed Web of Science ®Google Scholar
• Pfizer Ltd. Xinafoate salt of N4-(2,2-difluoro-4H-benzo-[1,4]-oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine. WO031011; 2009
   Google Scholar
• Rigel Pharmaceuticals, Inc. Method and device for administering xinafoate salt of N4-(2,2-difluoro-4H-benzo-[1,4]-oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine. WO059631; 2013
   Google Scholar
• Allan R, Jones I, Bartley M, et al. A randomised, placebo controlled trial of the effect of an inhaled syk inhibitor on allergen induced airways responses in mild asthma [abstract no A2774]. American Thoracic Society International Conference Meetings Abstracts; 2012
   Google Scholar
• Rigel Pharmaceuticals, Inc. A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma. Available from: https://clinicaltrials.gov/ct2/show/record/NCT01591044?term=Rigel+R343&rank=1
   Google Scholar
• Rigel Pharmaceuticals, Inc. Rigel’s R343 Did Not Meet Primary Endpoint in Asthma Study. Available from: http://ir.rigel.com/phoenix.zhtml?c=120936&p=irol-newsArticle&ID=1849671&highlight=
   Google Scholar
• Merck Sharp & Dohme Corp. Prodrug bipyridylaminopyridines as syk inhibitors. WO074421; 2014
   Google Scholar
• Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors. WO048065; 2014
   Google Scholar
• Merck Sharp & Dohme Corp. Pyrazolyl derivatives as syk inhibitors. WO192125; 2013
   Google Scholar
• Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors. WO192128; 2013
   Google Scholar
• Boehringer Ingelheim International Gmbh. Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments. WO156608; 2013
   Google Scholar
• Boehringer Ingelheim International Gmbh. Substituted quinolines and their use as medicaments. WO014060; 2013
   Google Scholar
• Ziarco Pharma Ltd. 2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinase (syk) inhibitors. WO045029; 2014
   Google Scholar
• Chung KF. p38 mitogen-activated protein kinase pathways in asthma and COPD. Chest 2011;139:1470-9
   PubMed Web of Science ®Google Scholar
• Pfizer. An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma. Available from: https://clinicaltrials.gov/ct2/show/NCT02219048?term=NCT02219048&rank=1
   Google Scholar
• Respivert Ltd. L-pyrazolyl-3-(4-((2-anilinopyrimidin-4 -yl)oxy)napththalen-1-yl) ureas as P38 MAP kinase inhibitors. WO050756; 2013
   Google Scholar
• Respivert Ltd. 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy) napththalen-1-yl) ureas as P38 MAP kinase inhibitors. WO050757; 2013
   Google Scholar
• Respivert Ltd. Kinase inhibitors. WO033446; 2014
   Google Scholar
• Respivert Ltd. Diaryl urea derivatives as P38 MAP kinase inhibitors. WO033447; 2014
   Google Scholar
• Respivert Ltd. Pyrazole derivatives as P38 MAP inhibitors. WO033448; 2014
   Google Scholar
• Respivert Ltd. Kinase inhibitors. WO033449; 2014
   Google Scholar
• Norman P. Respivert’s multikinase inhibitors, an evaluation of WO2014033446 to WO2014033449. Expert Opin Ther Pat 2014;24:1397-407
   Web of Science ®Google Scholar
• Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta. WO075392; 2014
   Google Scholar
• Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta. WO075393; 2014
   Google Scholar
• Norman P. Evaluation of WO2014075392 and WO2014075393, Merck’s first PI3Kδ inhibitor filings. Expert Opin Ther Pat 2014;24:1277-82
   PubMed Web of Science ®Google Scholar
• Gilead Calistoga LLC. Compositions and methods of treating a disease with (S)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile. WO116562; 2013
   Google Scholar
• Norman P. Evaluation of WO2013116562A, an orally active PI3Kδ inhibitor for the treatment of asthma. Expert Opin Ther Pat 2014;24:603-7
   PubMed Web of Science ®Google Scholar
• Respivert Ltd. Crystalline PI3 kinase inhibitors. WO136076; 2013
   Google Scholar
• Norman P. Evaluation of WO2013136076: two crystalline forms of the phosphatidylinositol 3-kinase-δ inhibitor RV-1729. Expert Opin Ther Pat 2014;24:471-5
   PubMed Web of Science ®Google Scholar
• Respivert Ltd. A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729. Available from: https://clinicaltrials.gov/ct2/show/NCT01813084?term=RV1729&rank=2
   Google Scholar
• Respivert Ltd. A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729 for up to 28 Days. Available from: https://clinicaltrials.gov/ct2/show?term=RV1729&rank=1
   Google Scholar
• A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of RV1729 for 28 Days in Patients With COPD. Available from: https://clinicaltrials.gov/ct2/show/NCT02140346?term=RV1729&rank=3
   Google Scholar
• Pfizer Ltd. Indazoles. WO014567; 2013
   Google Scholar
• Lu S, Liu N, Dass SB, et al. Randomized, placebo-controlled study of a selective PDE4 inhibitor in the treatment of asthma. Respir Med 2009;103:342-7
   PubMed Web of Science ®Google Scholar
• Singh D, Petavy F, Macdonald AJ, et al. The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Respir Res 2010;11:26
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim International Gmbh. Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma. WO026797; 2013
   Google Scholar
• Boehringer Ingelheim International Gmbh. Substituted piperidino-dihydrothienopyrimidines. WO050248; 2009
   Google Scholar
• Boehringer Ingelheim International Gmbh. Dihydrothienopyrimidine for treating inflammatory disorders. WO118793; 2007
   Google Scholar
• Boehringer Ingelheim International Gmbh. Dihydrothienopyrimidines for the treatment of inflammatory diseases. WO111549; 2006
   Google Scholar
• Pettipher R, Hunter MG, Perkins CM, et al. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459. Allergy 2014;69:1223-32
   PubMed Web of Science ®Google Scholar
• F. Hoffmann-LA Roche AG. Substituted naphthylacetic acids. WO127841; 2013
   Google Scholar
• F. Hoffmann-LA Roche AG. Piperidinyl naphthylacetic acids. WO087544; 2013
   Google Scholar
• F. Hoffmann-LA Roche AG. Alkenyl naphthylacetic acids for treating respiratory disorders. WO068322; 2013
   Google Scholar
• Boehringer Ingelheim International Gmbh. Novel and selective CCR2 antagonists. WO010839; 2013
   Google Scholar
• Xiang Y-Y, Wang S, Liu M, et al. A GABAergic system in airway epithelium is essential for mucus overproduction in asthma. Nat Med 2007;13:862-7
   Google Scholar
• UWM Research Foundation, Inc. Novel GABAA agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma. WO047413; 2014
   Google Scholar
• Cubist Pharmaceuticals, Inc. Inhibiting the transient receptor potential A1 ion channel. WO113671; 2014
   Google Scholar
• Schoenberger M, Althaus M. Novel small molecule epithelial sodium channel inhibitors as potential therapeutics in cystic fibrosis - a patent evaluation. Expert Opin Ther Pat 2013;23:1383-9
   PubMed Web of Science ®Google Scholar
• Parion Sciences, Inc. 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl (2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy) phenyl)butyl)carbamimidoyl) pyrazine-2-carboxamide. WO003386; 2013
   Google Scholar
• Glaxosmithkline LLC. Novel compounds. WO081643; 2014
   Google Scholar
• Glaxosmithkline LLC. Novel compounds. WO081644; 2014
   Google Scholar
• Glaxosmithkline LLC. Novel compounds. WO081645; 2014
   Google Scholar
• Bateman ED, Izquierdo JL, Harnest U, et al. Efficacy and safety of roflumilast in the treatment of asthma. Ann Allergy Asthma Immunol 2006;96:679-86
   PubMed Web of Science ®Google Scholar
• Baye J. Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease. P T 2012;37:149-61
   Google Scholar